Key Takeaways:
A new analysis of Telix Pharmaceuticals’ Phase 3 ZIRCON trial showed its Zircaix imaging agent was 98% predictive of renal malignancy, expanding its potential use beyond its primary target.
"This analysis shows that when TLX250-Px PET/CT is positive, it is highly predictive of renal malignancy, including beyond ccRCC," Aboubacar Kaba, a urologist at the University of California, Los Angeles and the paper's corresponding author, said.
The exploratory analysis, published in European Urology, reported a positive predictive value of 98%, sensitivity of 82%, and specificity of 87% for detecting all renal cancer subtypes. This compares to the original trial's 93% PPV for its primary endpoint, clear cell renal cell carcinoma (ccRCC).
The findings suggest Zircaix could be a powerful tool to non-invasively distinguish aggressive cancers from benign tumors, potentially altering treatment for nearly half of patients and reducing the need for invasive biopsies, according to a separate post-hoc study.
The new analysis evaluated centrally reviewed imaging and pathology data from the ZIRCON trial, focusing on whether the tracer, 89Zr-girentuximab, correlated with malignancy in non-clear cell renal cell carcinoma (nccRCC) as well. The company noted that essentially all false-positives for ccRCC in the original study were found to be other malignant kidney cancer subtypes.
"While ZIRCON was designed to address ccRCC, this analysis supports continued evaluation of TLX250-Px PET imaging across a broader spectrum of renal malignancies," David N. Cade, Group Chief Medical Officer at Telix, said. He added the results reduce the risk of overtreatment and support clinical adoption.
Telix clarified that these findings are from exploratory analyses and were not the basis of its Biologics License Application (BLA) submission to regulators. The current application focuses exclusively on the detection of ccRCC. Zircaix has not yet received marketing authorization in any jurisdiction.
The publication strengthens the clinical case for Zircaix ahead of a potential regulatory approval, suggesting a larger total addressable market than initially targeted. Investors will now watch for the FDA's decision on the pending BLA for ccRCC and any future plans to pursue a broader label.
This article is for informational purposes only and does not constitute investment advice.
